Five Years Post-Pandemic: Here’s What We’ve Learned About Long COVID

The year 2025 marks five years since the COVID-19 pandemic went global. Among the many who contracted COVID-19 and recovered from the acute infection, some feel as though the disease has changed their day-to-day health for the worse. Many report a “brain fog” in which it has become harder for them to focus or think clearly, while others have various symptoms, including fatigue, pain, or even digestion issues.

This collection of symptoms has many names, but it became most commonly known as “long COVID.” When it was first observed a few years ago, physicians and researchers were divided on how to define, diagnose, or even treat it. Even less was known about why long COVID occurs and who is at risk of developing it.

Today, the medical and research communities have come a long way in understanding and tackling long COVID, says David Putrino, PhD, Director of Rehabilitation Innovation at the Mount Sinai Health System. There are, unfortunately, still misconceptions about long COVID among patients and even some health providers, and dispelling such myths is key to proper treatment, he adds.

In this Q&A, Dr. Putrino discusses to say what is known about long COVID today.

Is there a clear definition for long COVID today?

Physicians now have clear clinical guidelines and criteria for diagnosing long COVID. According to the National Academies of Science, Engineering, and Medicine, long COVID is an infection-associated chronic condition whereby somebody who has survived an acute infection with SARS-CoV-2—the virus that causes COVID-19—fails to return to their pre-infection health status within a period of three months.

Long COVID symptoms can present in different ways:

  • Continuous, where symptoms remain constant and do not go away
  • Progressive, where symptoms worsen over time
  • Relapsing and remitting, where a patient can feel good for a while, and then have a period of feeling very poorly, and back and forth

“We need to start thinking about long COVID in the same way that cancer researchers have been thinking about cancer for the past three or four decades.” —David Putrino, PhD, Director of Rehabilitation Innovation at the Mount Sinai Health System

 

What different kinds of long COVID symptoms can patients have?

Long COVID has been described as a highly diverse disease state, with studies collectively noting more than 200 symptoms.

The most commonly reported symptom, which affects more than 90 percent of patients, tends to be fatigue and a phenomenon known as post-exertional malaise. The latter is a distinct kind of energy limiting illness where if you ask someone to perform an action—such as walking on a treadmill or riding a bike—they are able to do so. But after they exert themselves, they experience a significant worsening of symptoms or a cluster of new symptoms that persist weeks to months afterwards.

Cognitive symptoms are also common, such as a worsened ability to make decisions, plan things in advance, or even regulate emotions. People speak of “brain fog,” which includes changes in attention and in short- and long-term memory, and it is evident that SARS-CoV-2 infection can significantly affect cognition. In fact, a study published in The New England Journal of Medicine in 2024 showed that any person who survives a COVID-19 infection experiences, on average, a loss of six IQ points. This is a sobering fact that makes a strong case for all healthy individuals to avoid SARS-CoV-2 infections by taking the appropriate precautions.

Some people also report gastrointestinal disturbances. These can be wide-ranging, including having diarrhea, having to go to the bathroom more than usual, increased difficulty in food moving through the body, and/or extreme constipation. In addition, some might gain new intolerances to certain kinds of food, have difficulty finishing a meal, or reduced appetite.

Recently, researchers are discovering that around 50 percent of long COVID patients might have new-onset pain. This is a disease state that really affects every organ system.

In 2024, about 17 million adults report having long COVID
For adults with long COVID, 79% say long COVID has limited their activities
Of those who said long COVID limited their activities, 25% say it has done so by a lot
The group most likely to experience long COVID is adults ages 35-49
Women are more likely to experience long COVID than men, with 8.5% of women reporting past long COVID, compared to 5.2% for men
Source: CDC

Do we know why long COVID happens?

We are starting to understand that in some cases, it could be just one path causing the symptom. In other cases, it could be a combination of pathologies. Here’s what we have found so far:

  • Viral persistence: Different studies have identified the presence of SARS-CoV-2 remaining in the bodies of patients with long COVID, even after the acute COVID-19 phase. There is evidence of circulating viral antigens, spike proteins in plasma, viral fragments in the gut, and so forth. We are seeing that the persistence is not latent and it’s not harmless for people with long COVID—it’s causing problems.
  • Latent pathogen reactivation: For some people, even if persistent SARS-CoV-2 does not cause any damage to organs, it could have caused immune dysregulation, leading to reactivation of other latent viruses. There are studies that have shown herpes virus reactivations, such as Epstein-Barr virus, in patients with long COVID, and others showing reactivation of Bartonella infection as well. It may be that the SARS-CoV-2 viral infection kicks up other pathogens that were smoldering below the surface, causing inflammation and other problems.
  • Autonomic nervous system dysfunction: This is the part of your nervous system that controls blood pressure, digestion, sweating, and temperature control. And we’re seeing that the virus can knock this system out of balance. When it is disrupted, people can experience something called postural orthostatic tachycardia syndrome: when they go from lying down flat to standing, they experience unpredictable blood pressure and heart rate changes that can lead them to feel as though they’re about to pass out. This is frequently misdiagnosed as anxiety or panic attacks.
  • Autoimmunity: Relating to immune dysregulation, we are starting to see evidence that for a subset of people with long COVID, they have functional autoantibodies circulating in their body that are designed to attack and cause damage to the body’s own tissues. We have animal studies where mice that were injected with IgG antibodies from patients with long COVID started to develop symptoms similar to that of the patient, especially in new-onset pain, whereas that phenomenon was not seen in mice receiving IgG from healthy controls.
  • Hormonal dysregulation: There are multiple papers on long COVID impacts on hormones like cortisol, which affect wakefulness and inflammation, as well as androgenic hormones, such as testosterone and estradiol. So women with long COVID are much more likely to have extremely low levels of testosterone, and men with long COVID might have low levels of estradiol. This may also explain why long COVID is more frequently diagnosed in women compared with men.

Are there any misconceptions about long COVID?

For the clinical community, we’ve been focusing on getting out a main message, which is that long COVID requires a precision response. If a physician is asking, “Is there a cure—singular—for long COVID,” that is the wrong question. The correct question should be, “What are the tests and techniques I should be using to identify the symptoms of the patient with long COVID in front of me, and how do I proceed from there?”

We need to start thinking about long COVID in the same way that cancer researchers have been thinking about cancer for the past three or four decades. We have seen attitudes about cancer change, starting in the ‘80s when patients were told they got cancer because they had a “Type A” personality, to one today where a patient gets individualized treatment based on age, sex, gene profile, and so much more.

That’s the sort of precision we need in long COVID. What is your medical history? Your immune history? Any genetic expression that might predispose you to chronic illnesses?

Long COVID is classified as an infection-associated chronic condition, which includes chronic Lyme disease and myalgic encephalomyelitis/chronic fatigue syndrome. Historically, these chronic conditions have been viewed as largely psychogenic, and people have been told they can be cured with cognitive behavioral therapy and exercise.

I cannot stress how damaging this is to patients, and perhaps in 30 years, we will be looking back at our approaches and be ashamed of how we were framing long COVID for patients.

Long COVID affects many people, and it disproportionately affects young people too. These are people who are in their active, prime years and we need to help them lead their best lives.

A Mount Sinai Medical Student, Whose Work Helped a Young Boy Recover From Nearly Drowning, Reflects on Her Research and Aspirations

From left: Farid Khan, MBBS, co-chair of the Fellows in Training Program of the New York Chapter of the American College of Cardiology; Helen Gordan; and Samuel Kim, MD, the chapter’s program chair

Helen Gordan, a second-year medical student at the Icahn School of Medicine at Mount Sinai, recently won best clinical case abstract at the New York Chapter of the American College of Cardiology Fellows in Training competition.

Her abstract titled “Unraveling a Genetic Diagnosis After a Near Drowning Incident” describes the diagnostic odyssey of a 9-year-old boy who was cared for at Mount Sinai Kravis Children’s Hospital after he was resuscitated from near-drowning in a swimming pool.

Careful sleuthing ultimately elicited a novel cardiac genetic cause. The patient made a full recovery and is being treated successfully, and the genetic discovery will permit others to benefit in the future.

Ms. Gordan’s award is all the more impressive for having won it as a second-year medical student, competing against much more senior trainees in internal medicine and cardiology fellowship training.  Ms. Gordan presented the work in an oral presentation in December.

In a Q&A, Ms Gordan discusses why she chose the Icahn School of Medicine at Mount Sinai, what has drawn her to explore pediatric cardiology as a potential career choice, and her research interests.

What inspired you to explore pediatric cardiology as a medical student?

From the beginning of medical school, I was drawn to specialties that offer meaningful long-term patient relationships and combine medical management with precise interventions. Pediatric cardiology fulfills both these criteria and more. Since every heart is unique, cardiologists must rely on fundamental physiologic principles to tailor treatments to each case. The opportunity for early intervention, especially in congenital heart defects, has an immeasurable impact on long-term outcomes, enabling children to thrive and lead full lives. It opens the door to the kind of long-term relationships with patients and families that I desire in my career.

What are your research interests?

My research interests lie at the intersection of engineering and clinical care. My undergraduate degree is in electrical engineering, so I am particularly interested in how technology can be harnessed to both enhance therapeutic outcomes and improve access to care for underserved populations. For example, asynchronous online care platforms—which allow physicians to assess patient concerns and provide treatment through messaging, patient portals, or online questionnaires— offer unique opportunities to bridge gaps in accessibility, especially for resource-limited settings. Understanding how these models can integrate with chronic disease management, including heart disease, is a growing area of interest.

What does winning this abstract award mean to you and how will it help propel your studies?

I was incredibly excited and honored to win this case competition. It has encouraged me to continue to explore challenging questions and raise questions about frameworks for diagnoses. It has allowed me to receive feedback from experts that have both refined my skills and broadened my perspective. Most importantly, it has underscored the importance of great mentorship and collaboration. I am incredibly grateful for the support I received from Dr. Barry Love and Dr. Amy Kontorovich while working on this case.

Why did you choose the Icahn School of Medicine school and how has the medical school experience been so far?

The Icahn School of Medicine stood out to me because of its emphasis on fostering diverse academic backgrounds. Coming from an engineering discipline, I was eager to join a medical institution that values multidisciplinary approaches to problem-solving and allows students to incorporate their own interests into their clinical training. The culture of innovation and research has completely exceeded these expectations. I have been able to learn about entrepreneurship in medicine through Sinai BioDesign’s THRIVE program, explore access-to-care barriers through a summer global health research program, and explore different specialties with the support of amazing faculty. My experience has been exceptional, largely due to the supportive mentorship I’ve received from Dr. Love, Dr. Gault, and many others.

What do you hope your impact will be on patients, field, and practice?

First and foremost, I hope to be an exceptional clinician. I would like to provide the expertise and empathy patients need when facing scary and vulnerable moments. I also aspire to combine innovation with equitable care to make an impact. I hope to provide solutions that enhance quality of life while ensuring accessibility to care, regardless of socioeconomic or geographic barriers. Ultimately, I want my career to serve as a bridge between disciplines and help to drive advancements that improve both individual patient experiences and systemic health care delivery.

New Curriculum for the Master of Science in Biomedical Science Program Provides More Options for Students

Jose Silva, PhD, left, Program Director, Master of Science in Biomedical Science, and Professor, Pathology, Molecular and Cell Based Medicine, and Oncological Sciences, shown in his lab.

The Graduate School of Biomedical Sciences, part of the Icahn School of Medicine at Mount Sinai, has announced a new curriculum structure for its Master of Science in Biomedical Science (MSBS) program.

The MSBS program, started in 2005, features the multidisciplinary research education available at the school, a commitment to translating fundamental biomedical research into disease prevention and novel therapies, and a dedication to preparing students to contribute to the biomedical enterprise in the non-profit or for-profit sectors.

The program prepares students for a range of health-related advanced degree programs and careers, whether focused on medicine, such as the MD program; research, such as the PhD and MD-PhD programs; or manager-level employment in the clinical and industrial sectors. Eligible students should have a degree in science or a related discipline from an accredited college or university.

“For 20 years, our MSBS program has successfully prepared our students for future success in advance degree programs. Nonetheless, we recognized that a changing job environment required us to provide students with more options, and the new program structure does just that,” says Eric Sobie, PhD, Senior Associate Dean for Master’s in Basic Science Programs.

The program has been restructured to address the changing educational landscape. The new MSBS program offers four distinct tracks that target different types of students and provide greater flexibility for how students can complete the program. The total minimum credits has been reduced from 45 to 36 credits over two to four semesters.

Students will choose their track based on their career goals and stage of life:

  • Track 1: Post-Baccalaureate Pre-doctoral (pre-PhD or pre-MD-PhD): This full-time, four-semester track requires students to complete a master’s thesis based on original laboratory research and features a staggered block schedule to facilitate focused study. Students will learn the fundamentals of biomedical sciences while engaging in hands-on research in the laboratories of their chosen Principal Investigators.
  • Track 2: Post-Baccalaureate Pre-medical (pre-MD): This full-time, three-semester track also follows a block schedule structure. Students graduate with a capstone project and a final comprehensive examination. This track allows students interested in applying to MD programs to better prepare for the MCAT exam by offering a lighter course load during the spring semester. Students also benefit from non-curricular experiences available at The Mount Sinai Hospital, such as clinical shadowing.
  • Track 3: Industry/Clinical/Professional Development: This flexible track, available in three or four semesters, combines a block schedule alongside a capstone project. It caters to individuals working in the clinical, educational, or private sector who aim to enhance their skills and advance their careers into higher-ranked, better-paid positions.
  • Track 4: Accelerated Industry/Clinical/Professional Development: This faster-paced version of Track 3 consists of two full-time semesters with a block schedule, a capstone project and a final comprehensive examination. It is designed for individuals seeking to enhance their skills within a condensed time frame.

“Our new curriculum retains our unique hands-on training while offering more options and flexible tracks to support your career goals. Whether you’re interested in research, healthcare, or industry, and whether you’re a recent graduate or a professional looking to advance, we’re committed to helping you gain the knowledge and experience needed to take your career to the next level,” says Jose Silva, PhD, MSBS Program Director and Professor, Pathology, Molecular and Cell Based Medicine, and Oncological Sciences.

These tracks will continue to leverage the multidisciplinary training areas available at the Icahn School of Medicine at Mount Sinai through the PhD programs in Biomedical Sciences, Neuroscience, and the recent joint PhD program in Health Sciences in Engineering with the Rensselaer Polytechnic Institute. This structure allows students to earn a specific concentration or specialization notation on their transcripts by completing a minimum of six credits in concentration-related elective courses, in addition to the required courses and a thesis or capstone project in concentration-related fields.

Students can choose from nine specialty areas to tailor their studies, including:

  • Cancer Biology
  • Disease Mechanisms and Therapeutics
  • Development, Regeneration, and Stem Cells
  • Immunology
  • Genetics and Genomics
  • Microbiology
  • Neuroscience
  • Artificial Intelligence and Emerging Technologies in Medicine
  • Health Sciences in Engineering

Visit our website or contact us to learn more about this program and find out which track aligns with your schedule and career goals.

Here’s What New Yorkers Need to Know About the Bird Flu

You’ve probably heard about it on the news: The bird flu is causing concern.

While the current public health risk is low, the U.S. Centers for Disease Control and Prevention (CDC) is working with local health experts and watching the situation carefully.

Nicholas R. Sells, MD, FACP, FIDSA

“The key message is that people should not be worried. We believe the risk to the population is low,” says Nicholas R. Sells, MD, FACP, FIDSA, Medical Director of Infection Prevention, Mount Sinai Morningside, and Associate Professor of Medicine (Infectious Diseases) at the Icahn School of Medicine at Mount Sinai.

New York Gov. Kathy Hochul delivered the same message—that there was no public health threat—when she recently ordered the temporary closure of bird poultry markets in New York City to allow for special cleaning and inspections.

Here are five key takeaways to keep you updated on the bird flu, also known as avian influenza.

Why the risk to the public is low: Bird flu, which has circulated for decades, is now widespread in wild birds worldwide and is causing outbreaks in poultry and dairy cows in the United States. There have been several recent human cases among dairy and poultry workers. The risk to the general public is low because the current strain of this virus cannot easily spread from person to person, experts say.

Eggs, chicken, and milk: News about the bird flu has prompted some questions among the general public, and experts like Dr. Sells are emphasizing that it is safe to eat eggs and chicken, and drink pasteurized milk that you buy in the store. That’s because the bird flu is not transmissible by eating properly prepared and cooked poultry and eggs. Proper cooking and pasteurization kills the bird flu virus and other dangerous microbes. Milk and infant formula you buy in the store are also safe for infants and children, according to the American Academy of Pediatrics.

What the experts are doing: The CDC is using its flu surveillance systems to monitor for bird flu activity in people. According to the CDC, flu viruses change over time, so there is a risk the virus could be become more easily spread among people. At Mount Sinai, epidemiologists have been in touch with the CDC and the New York State and New York City health departments and have alerted health care providers through the Health System to be on the lookout for patients who may show signs of infection and to review their protocols for testing if needed. The reported signs and symptoms of bird flu virus infections in humans have ranged from no symptoms or mild to severe and include eye redness, fever, cough, and sore throat.

Here’s what you can do: Avoid contact with sick or dead wild birds, poultry and other animals, including dairy cows. Do not touch or consume raw milk or raw milk products or feed them to pets. Cook poultry, eggs and beef to the appropriate internal temperatures.

What about my pets? Bird flu viruses mainly infect wild migratory water birds and domestic poultry. Some bird flu viruses can spread to other animals. Cats and dogs could potentially eat or be exposed to sick or dead birds infected with bird flu viruses, and they could become infected. If your pet is showing signs of illness of a bird flu infection and has been exposed to infected (sick or dead) wild birds/poultry, you should monitor your health for signs of fever or infection.  According to the CDC, it is unlikely you can get sick with bird flu from your infected pet, but it is possible.

Is it the Flu or Maybe Something Else? Symptoms of Common Respiratory Illnesses Can Also Be Signs of Potential Heart Complications.

Did you know that some of the symptoms of the common respiratory illnesses that typically spread during the winter months mimic the symptoms of cardiovascular disease?

For example, if you are feeling short of breath or having chest pain, you may think it’s the flu. But it may be something else, especially if you have heart disease or are at risk for it.

That’s why the experts at Mount Sinai Fuster Heart Hospital are warning about the risk of heart problems during the time that respiratory illnesses typically surge, which also coincides with American Heart Month in February.

With a recent surge in influenza, COVID-19, norovirus, respiratory syncytial virus (RSV), and other respiratory viruses, it’s critical to pay close attention to your heart and symptoms—especially if you have heart disease or the risk factors for it, according to the experts. The combination of these four viruses has been termed a “quad-demic” as they are circulating at elevated levels this winter, according to the Centers for Disease Control and Prevention.

Symptoms of respiratory illness can mimic those of cardiovascular disease or cardiac events in high-risk groups. Some patients may think that symptoms such as being short of breath, weak, cold, or feverish, or having dizziness or chest pain may be solely a result of these winter viruses, but these symptoms could also be associated with, and masking, dangerous cardiovascular complications such as heart attack, pulmonary embolism, viral myocarditis, pericarditis, or even heart failure.

“We have seen people mistaking virus symptoms for serious heart complications. For example, some patients have shortness of breath, wheezing, coughing, swelling, and palpitations, and assume their symptoms are linked to a cold, when in fact they were actually in heart failure. Other patients who have had persistent chest pain and palpitations after acute viral illness may need to consider that, in fact, this could be myocarditis,” says Johanna Contreras, MD, a cardiologist at Mount Sinai Fuster Heart Hospital.

“Don’t ignore these symptoms thinking they are just a long-lasting viral infection, especially if you’re at high risk of heart disease, as this disease can be treated promptly and avoid long-term complications,” says Dr. Contreras. “Make sure to consult your doctor or call 911 if you have worsening chest pain, dizziness, or shortness of breath—a serious cardiac condition can progress quickly and it’s key to catch complications early, before they become life-threatening.”

The recent surge in viruses can also trigger cardiovascular complications among those with established heart conditions, including fever, dehydration, and increased inflammation, and Mount Sinai cardiologists are seeing a rise in these cases across all age groups.

Patients with underlying cardiovascular disease and the associated risk factors are at increased risk. Inflammation can trigger heart attacks in people with coronary artery disease. It can also exacerbate heart failure symptoms and irregular or rapid heartbeats, leading to hospitalization. Doctors have also seen post-viral myocarditis—inflammation around the heart that can progress to complications such as heart failure and cardiogenic shock—in otherwise healthy patients.

“In fact, anyone is susceptible, even health care providers themselves are susceptible, and anyone who is not paying attention to their symptoms may get sick with potentially life threatening complications,” says Icilma Fergus, MD, Director of Cardiovascular Disparities for the Mount Sinai Health System. “A recent patient had severe shortness of breath, weakness, palpitations and fatigue, fearing they had heart failure. After they had bloodwork taken, there was a frantic moment when we could not reach the patient to share results that revealed a significantly elevated troponin level which can be linked to a heart attack. Although we suspected the worst, we eventually reached the patient and they were hospitalized with Influenza A and severe viral myocarditis. They were treated appropriately and luckily there was a good outcome.”

“If you get sick and have chest pain or are out of breath, or have swelling of the legs, and it’s getting worse—especially if you have an underlying heart condition or risk factors such as obesity, diabetes, or a family history of heart disease—your symptoms of a viral infection may in fact represent cardiac symptoms,” says Anuradha Lala, MD, a cardiologist at Mount Sinai Fuster Heart Hospital. “While the immune system’s primary job is to eliminate the virus, the inflammatory response can inadvertently harm cardiac tissue. Thus, if you have a known heart condition, viral infections can bring on exacerbations—or a worsening of the underlying issue—whether it is atrial fibrillation, coronary heart disease, or heart failure.”

Heart Disease Statistics

Heart disease is the leading cause of death among men and women in the United States. Nearly half of adults—more than 121 million people—have some type of cardiovascular disease. According to the Centers for Disease Control and Prevention, more than 700,000 people die of heart disease annually, and 80 percent of these cases are preventable.

High-Risk Groups

Anyone can get heart disease, but people are more susceptible if they have cardiovascular risk factors such as high cholesterol, high blood pressure, diabetes, being overweight, or using tobacco. Age is also a factor, specifically for menopausal women (between 45 and 55) and men older than 55, and men with a family history also are at higher risk. Getting less than six hours of sleep a night may also contribute to poor outcomes.

Certain groups, including African American and Hispanic/Latino people as well as new immigrants, may also be at higher risk of complications from untreated viral illnesses. However, risk for cardiovascular disease in any population can be decreased by taking simple steps toward a healthier lifestyle.

Tips for Lowering Risk of Heart Disease

  • Know your family history
  • Be aware of five key numbers cited by the American Heart Association: blood pressure, total cholesterol, HDL (or “good”) cholesterol, body mass index, and fasting glucose levels
  • Maintain a healthy diet, eating nutrient-rich food and eliminating sweets
  • Limit alcohol consumption to no more than one drink per day for women and men
  • Quit using tobacco or other inhaled substances, including both smoking and electronic cigarettes/vapes
  • Watch your weight and exercise regularly
  • Learn the warning signs of heart attack and stroke, including chest discomfort; shortness of breath; pain in the arms, back, neck, or jaw; breaking out in a cold sweat; and lightheadedness
  • Find practical ways to eliminate stress and focus on mental health

Research Suggests Link Between COVID-19 Vaccine Hesitancy and Increasing Uncertainty in Routine Vaccines for Young Children

Eric G. Zhou, PhD

Young children of parents who declined the COVID-19 vaccine were about 25 percent less likely to receive vaccination against measles, mumps, and rubella (MMR), according to the results of a new study. Historic political and socioeconomic disparities remain important predictors of MMR vaccine hesitancy, but the pandemic appears to have further increased MMR skepticism, researchers said.

 “Our research highlights the link between parental characteristics and MMR vaccine uptake, showing how pandemic-related hesitancy may affect other routine vaccines,” said Eric G. Zhou, PhD, Instructor, Pediatrics, Cardiology, and Population Health Science and Policy at the Icahn School of Medicine at Mount Sinai, a lead author of the study. “Addressing these disparities, through equitable access and fostering trust and transparency in vaccine safety, is key to protecting children from preventable diseases like measles.”

The researchers conducted a cross-sectional study from July 2023 to April 2024 using a digital health survey to examine national population characteristics.

They analyzed responses from more than 19,000 parents of children younger than 5 years old to examine the association between self-reported parental characteristics (i.e., sociodemographics, politics, COVID-19 vaccination status) and children’s MMR vaccination rates, using logistic regression. The study was published January 16 in the American Journal of Public Health.

Children of parents who received at least one dose of the COVID-19 vaccine had higher MMR vaccination rates (80.8 percent) than did children of unvaccinated parents (60.9 percent). The researchers found higher MMR vaccination rates in the Northeast and Midwest regions of the United States.

 “In the United States, we are experiencing a concerning resurgence of childhood vaccine-preventable diseases,” said Ben Rader, PhD, of Boston Children’s Hospital, the study’s corresponding author. “Our research suggests that COVID-19 vaccine hesitancy has fueled increasing MMR vaccine hesitancy, leaving children more vulnerable to highly contagious and life-threatening illnesses like measles.”

Pin It on Pinterest